LONA

SEC source: 0001209191-22-039342 · doc4.xml · nonDerivative · entry 2

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,781

F4 · shares: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs were scheduled to vest according to the following schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout") and (3) one third (1/3rd) of the number of shares subject to the RSU award vest six (6) months after the LIFT-AD Readout, in each case subject to continued service with the Issuer through the applicable vesting date. On June 22, 2022, the Issuer completed the public readout of topline results of the ACT-AD Phase 2 clinical trial and 10,000 RSUs vested and settled on such date.

SEC source: 0001209191-22-036067 · doc4.xml · derivative · entry 3

CHURCH KEVIN · CIK 0001822499 · Executive VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,110

Underlying: Common Stock · 2,500 shares

Expires 2028-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.

SEC source: 0001209191-22-036067 · doc4.xml · nonDerivative · entry 2

CHURCH KEVIN · CIK 0001822499 · Executive VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,309

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-032690 · doc4.xml · derivative · entry 1

EDELMAN JOSEPH · CIK 0001164426 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,871

Underlying: Common Stock · 13,871 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.

SEC source: 0001209191-22-032699 · doc4.xml · derivative · entry 1

PICKERING GRANT · CIK 0001258693 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,467

Underlying: Common Stock · 3,467 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.

SEC source: 0001062993-22-013738 · form4.xml · derivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,871

Underlying: Common Stock · 13,871 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 28, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022.

F2 · ownership.nature: Consists of options to purchase shares of the Issuer's common stock awarded to Joseph Edelman in connection with his role as a member of the Issuer's Board of Directors. Mr. Edelman is the managing member of Perceptive Advisors LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset.

SEC source: 0001209191-22-032684 · doc4.xml · derivative · entry 1

JOHNSON JAMES A · CIK 0001225501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,871

Underlying: Common Stock · 13,871 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.

SEC source: 0001209191-22-032687 · doc4.xml · derivative · entry 1

FLUKE JOHN M JR · CIK 0001191906 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,871

Underlying: Common Stock · 13,871 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.

SEC source: 0001209191-22-032693 · doc4.xml · derivative · entry 1

Kosacz Barbara · CIK 0001763316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,871

Underlying: Common Stock · 13,871 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.

SEC source: 0001209191-22-032696 · doc4.xml · derivative · entry 1

Romano Kelly A · CIK 0001722055 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,871

Underlying: Common Stock · 13,871 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.

SEC source: 0001209191-22-032681 · doc4.xml · derivative · entry 1

Panzara Michael A. · CIK 0001679039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,311

Underlying: Common Stock · 2,311 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.

SEC source: 0001209191-22-036067 · doc4.xml · nonDerivative · entry 1

CHURCH KEVIN · CIK 0001822499 · Executive VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,809

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · date: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022.

SEC source: 0001209191-22-039344 · doc4.xml · nonDerivative · entry 1

Worthington Mark · CIK 0001861464 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,711

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · date: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022.

SEC source: 0001209191-22-039340 · doc4.xml · nonDerivative · entry 1

Litton Mark James · CIK 0001604834 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,515

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · date: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022.

SEC source: 0001209191-22-039343 · doc4.xml · nonDerivative · entry 1

MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,955

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · date: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022.

SEC source: 0001209191-22-039342 · doc4.xml · nonDerivative · entry 1

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,781

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c).

F2 · date: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022.

SEC source: 0001209191-22-024219 · doc4.xml · derivative · entry 2

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,000

Underlying: Common Stock · 3,000 shares

Expires 2032-01-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-024219 · doc4.xml · nonDerivative · entry 1

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-022001 · doc4.xml · nonDerivative · entry 1

Romano Kelly A · CIK 0001722055 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,315

SEC source: 0001209191-22-020266 · doc4.xml · derivative · entry 1

Panzara Michael A. · CIK 0001679039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,742

Underlying: Common Stock · 27,742 shares

Expires 2032-03-17

F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option will vest on April 18, 2022 and one thirty-sixth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-011485 · doc4.xml · derivative · entry 2

CHURCH KEVIN · CIK 0001822499 · Executive VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,152 shares

Expires 2027-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option fully vested on September 1, 2017.

SEC source: 0001209191-22-011485 · doc4.xml · nonDerivative · entry 1

CHURCH KEVIN · CIK 0001822499 · Executive VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,566

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-005622 · doc4.xml · derivative · entry 1

PICKERING GRANT · CIK 0001258693 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,742

Underlying: Common Stock · 27,742 shares

Expires 2032-01-26

F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option will vest on February 27, 2022 and one thirty-sixth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-005628 · doc4.xml · derivative · entry 5

Litton Mark James · CIK 0001604834 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2032-01-26

F7 · derivative.exercise_date: One-forty eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-004118 · doc4.xml · derivative · entry 2

CHURCH KEVIN · CIK 0001822499 · Executive VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-01-17

F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-004122 · doc4.xml · derivative · entry 1

Worthington Mark · CIK 0001861464 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2032-01-17

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-004129 · doc4.xml · derivative · entry 1

Lenington Rachel · CIK 0001861194 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2032-01-17

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-004123 · doc4.xml · derivative · entry 1

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2032-01-17

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-004120 · doc4.xml · derivative · entry 2

MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2032-01-17

F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.

SEC source: 0001209191-22-002218 · doc4.xml · derivative · entry 3

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,305 shares

Expires 2028-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to the option fully vested on January 1, 2022.

SEC source: 0001209191-22-002218 · doc4.xml · nonDerivative · entry 2

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-002218 · doc4.xml · nonDerivative · entry 1

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,755

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · date: The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.

SEC source: 0001209191-22-004118 · doc4.xml · nonDerivative · entry 1

CHURCH KEVIN · CIK 0001822499 · Executive VP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,414

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · deemedExecutionDate: The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.

SEC source: 0001209191-22-004120 · doc4.xml · nonDerivative · entry 1

MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,256

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · date: The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.

SEC source: 0001209191-22-005628 · doc4.xml · nonDerivative · entry 1

Litton Mark James · CIK 0001604834 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,758

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).

F2 · date: The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.

F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.

SEC source: 0001209191-21-063208 · doc4.xml · derivative · entry 1

Worthington Mark · CIK 0001861464 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-11-02

F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on June 1, 2022 and one-fourth of the shares subject to the option vest on each subsequent anniversary thereafter.

SEC source: 0001209191-21-063207 · doc4.xml · derivative · entry 1

Lenington Rachel · CIK 0001861194 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-11-02

F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on June 14, 2022 and one-fourth of the shares subject to the option vest on each subsequent anniversary thereafter.

SEC source: 0001209191-21-052564 · doc4.xml · derivative · entry 6

Litton Mark James · CIK 0001604834 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,880

Underlying: Common Stock · 50,440 shares

Expires 2029-08-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: One-fourth of the shares subject to the option vested on July 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.

SEC source: 0001209191-21-052564 · doc4.xml · nonDerivative · entry 2

Litton Mark James · CIK 0001604834 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-047601 · doc4.xml · derivative · entry 5

MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,763

Underlying: Common Stock · 15,762 shares

Expires 2029-08-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.

SEC source: 0001209191-21-047601 · doc4.xml · derivative · entry 4

MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,610 shares

Expires 2029-06-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to the option fully vested on April 1, 2021.

SEC source: 0001209191-21-047601 · doc4.xml · nonDerivative · entry 3

MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-047601 · doc4.xml · nonDerivative · entry 2

MOEBIUS HANS · CIK 0001822494 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,665

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-041084 · doc4.xml · nonDerivative · entry 2

FLUKE JOHN M JR · CIK 0001191906 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,884

F4 · kind: Acquisition by the Reporting Person pursuant to the Distribution.

F4 · price: Acquisition by the Reporting Person pursuant to the Distribution.

SEC source: 0001209191-21-041084 · doc4.xml · nonDerivative · entry 1

FLUKE JOHN M JR · CIK 0001191906 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Fluke Capital Management, L.P.

Disclosed balance after: 3,731

F1 · kind: Fluke Capital Management, L.P. distributed these shares to its partners on a pro rata basis for no consideration (the "Distribution").

F1 · price: Fluke Capital Management, L.P. distributed these shares to its partners on a pro rata basis for no consideration (the "Distribution").

F2 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3 · ownership.nature: The Reporting Person is a director of Fluke Management Corp., which is the managing general partner of Fluke Capital Management, L.P. The Reporting Person is also a partner of Fluke Capital Management, L.P. By virtue of such relationships, Mr. Fluke may be deemed to have voting and investment power with respect to the shares held by Fluke Capital Management, L.P. and as a result may be deemed to have beneficial ownership of such shares.

SEC source: 0001209191-21-039627 · doc4.xml · derivative · entry 3

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,305

Underlying: Common Stock · 6,305 shares

Expires 2028-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to the option fully vested on January 1, 2021.

SEC source: 0001209191-21-039627 · doc4.xml · nonDerivative · entry 2

MILESON GLENNA · CIK 0001822241 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-039242 · doc4.xml · derivative · entry 2

CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,152 shares

Expires 2026-08-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option fully vested on September 1, 2016.

SEC source: 0001209191-21-039242 · doc4.xml · nonDerivative · entry 1

CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,133

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-039625 · doc4a.xml · derivative · entry 3

CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,152 shares

Expires 2026-08-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to the option fully vested on September 1, 2016.